343 related articles for article (PubMed ID: 36884274)
41. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
42. Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer.
Cocks K; Wells JR; Johnson C; Schmidt H; Koller M; Oerlemans S; Velikova G; Pinto M; Tomaszewski KA; Aaronson NK; Exall E; Finbow C; Fitzsimmons D; Grant L; Groenvold M; Tolley C; Wheelwright S; Bottomley A;
Eur J Cancer; 2023 Jan; 178():128-138. PubMed ID: 36436330
[TBL] [Abstract][Full Text] [Related]
43. Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival.
Quinten C; Maringwa J; Gotay CC; Martinelli F; Coens C; Reeve BB; Flechtner H; Greimel E; King M; Osoba D; Cleeland C; Ringash J; Schmucker-Von Koch J; Taphoorn MJ; Weis J; Bottomley A
J Natl Cancer Inst; 2011 Dec; 103(24):1851-8. PubMed ID: 22157640
[TBL] [Abstract][Full Text] [Related]
44. The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study.
Ramsenthaler C; Osborne TR; Gao W; Siegert RJ; Edmonds PM; Schey SA; Higginson IJ
BMC Cancer; 2016 Jul; 16():427. PubMed ID: 27387201
[TBL] [Abstract][Full Text] [Related]
45. Selecting a Subset Based on the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events for Patient-Reported Symptom Monitoring in Lung Cancer Treatment: Mixed Methods Study.
Veldhuijzen E; Walraven I; Belderbos J
JMIR Cancer; 2021 Sep; 7(3):e26574. PubMed ID: 34519658
[TBL] [Abstract][Full Text] [Related]
46. Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Twelves C; Cortés J; O'Shaughnessy J; Awada A; Perez EA; Im SA; Gómez-Pardo P; Schwartzberg LS; Diéras V; Yardley DA; Potter DA; Mailliez A; Moreno-Aspitia A; Ahn JS; Zhao C; Hoch U; Tagliaferri M; Hannah AL; Rugo HS
Eur J Cancer; 2017 May; 76():205-215. PubMed ID: 28360015
[TBL] [Abstract][Full Text] [Related]
47. Self-Reported Quality of Life and Symptom Burden in Ambulatory Patients With Multiple Myeloma on Disease-Modifying Treatment.
Kiely F; Cran A; Finnerty D; O'Brien T
Am J Hosp Palliat Care; 2017 Aug; 34(7):671-676. PubMed ID: 27141015
[TBL] [Abstract][Full Text] [Related]
48. Association of Disease Progression With Health-Related Quality of Life Among Adults With Breast, Lung, Pancreatic, and Colorectal Cancer.
Marschner N; Zacharias S; Lordick F; Hegewisch-Becker S; Martens U; Welt A; Hagen V; Gleiber W; Bohnet S; Kruggel L; Dille S; Nusch A; Dörfel S; Decker T; Jänicke M
JAMA Netw Open; 2020 Mar; 3(3):e200643. PubMed ID: 32154886
[TBL] [Abstract][Full Text] [Related]
49. Worsening of rest-activity circadian rhythm and quality of life in female breast cancer patients along progression of chemotherapy cycles.
Sultan A; Choudhary V; Parganiha A
Chronobiol Int; 2017; 34(5):609-623. PubMed ID: 28276853
[TBL] [Abstract][Full Text] [Related]
50. Clinicians versus patients subjective adverse events assessment: based on patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
Liu L; Suo T; Shen Y; Geng C; Song Z; Liu F; Wang J; Xie Y; Zhang Y; Tang T; Zhang L; Wang W
Qual Life Res; 2020 Nov; 29(11):3009-3015. PubMed ID: 32564293
[TBL] [Abstract][Full Text] [Related]
51. The Azeri Version of European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30): Translation and Validation.
Davudov MM; Harirchi I; Amiraliyev N; Mehtiyeva E; Mirzajani Z; Amiraliyev K; Rustamli N; Zebardast J; Montazeri A
Asian Pac J Cancer Prev; 2020 Jan; 21(1):267-271. PubMed ID: 31983195
[TBL] [Abstract][Full Text] [Related]
52. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
53. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life.
Bergman B; Aaronson NK; Ahmedzai S; Kaasa S; Sullivan M
Eur J Cancer; 1994; 30A(5):635-42. PubMed ID: 8080679
[TBL] [Abstract][Full Text] [Related]
54. Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).
Hagelstein V; Ortland I; Wilmer A; Mitchell SA; Jaehde U
Ann Oncol; 2016 Dec; 27(12):2294-2299. PubMed ID: 27681863
[TBL] [Abstract][Full Text] [Related]
55. Linking the European Organisation for Research and Treatment of Cancer Item Library to the Common Terminology Criteria for Adverse Events.
Gilbert A; Piccinin C; Velikova G; Groenvold M; Kuliś D; Blazeby JM; Bottomley A
J Clin Oncol; 2022 Nov; 40(32):3770-3780. PubMed ID: 35973158
[TBL] [Abstract][Full Text] [Related]
56. Linguistic Validation of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Korean.
Cho J; Yoon J; Kim Y; Oh D; Kim SJ; Ahn J; Suh GY; Nam SJ; Mitchell SA
J Glob Oncol; 2019 Mar; 5():1-10. PubMed ID: 30917069
[TBL] [Abstract][Full Text] [Related]
57. Health-related quality of life among cervical cancer survivors at a tertiary hospital in Ghana.
Amo-Antwi K; Agambire R; Konney TO; Nguah SB; Dassah ET; Nartey Y; Appiah-Kubi A; Tawiah A; Tannor EK; Peprah A; Ansah MB; Sam D; Akakpo PK; Ankobea F; Djokoto RM; Idun MYK; Opare-Addo HS; Opoku BK; Odoi AT; Johnston C
PLoS One; 2022; 17(6):e0268831. PubMed ID: 35657957
[TBL] [Abstract][Full Text] [Related]
58. Telephone interventions for symptom management in adults with cancer.
Ream E; Hughes AE; Cox A; Skarparis K; Richardson A; Pedersen VH; Wiseman T; Forbes A; Bryant A
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD007568. PubMed ID: 32483832
[TBL] [Abstract][Full Text] [Related]
59. Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy.
Knoerl R; Gray E; Stricker C; Mitchell SA; Kippe K; Smith G; Dudley WN; Lavoie Smith EM
Support Care Cancer; 2017 Nov; 25(11):3437-3446. PubMed ID: 28577231
[TBL] [Abstract][Full Text] [Related]
60. Recovery of health-related quality of life in patients undergoing robot-assisted radical cystectomy with intracorporeal diversion.
Abozaid M; Tan WS; Khetrapal P; Baker H; Duncan J; Sridhar A; Briggs T; Selim M; Abdallah MM; Elmahdy AA; Elserafy F; Kelly JD
BJU Int; 2022 Jan; 129(1):72-79. PubMed ID: 34092021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
